9 results
The primary objective is to assess the effect of tDCS using different electrode configurations on corticomotor excitability in the lower extremities of chronic stroke survivors and healthy subjects. Secondary objectives are (a) to assess the effect…
To determine the instantaneous effects of cerebellar tDCS during PFT on posturographical and neurophysiological parameters in stroke patients and healthy subjects.
Primary objectives:To characterize the pharmacokinetics of the 300 mg trientine capsule with a fast dissolution profile.To assess the effect of dissolution rate on the pharmacokinetics of trientine.To assess the effect of food on the…
The primary objective of this study is to evaluate and compare the plasma PK parameters of TETA and its two metabolites (MAT and DAT) after two dose levels of Syprine® capsules and TETA 4HCL tablets in adult healthy male and female volunteers.The…
We focus on a previous study showing enhanced motor sequence learning performance in OA when coupled with active tDCS stimulation. In their study, Zimerman et al. (2013) found a facilitating effect of M1 anodal tDCS on sequence learning in OA, these…
To evaluate the effects of tDCS on information processing speed in comparison to sham tDCS in patients after stroke with ascertained reduced processing speed. A proof of principle study.
The objective of this study is:- to estimate the electrical conductivity of the chronic stroke lesion and the variance on this within chronic stroke subjectsSecondary:- derive functional organisation of the motor system of the upper extremity…
We aim to investigate the relationship between positive schema activation and subsequent tests of emotional schema memory, and whether tDSC during positive schema activation can facilitate retrieval of emotional memory for positive information in…
Primary objective:Part 1: To determine the safety, tolerability, and RP2D of a daily dosing schedule (induction) of GSK3745417 Part 2: To evaluate clinical efficacy following the daily dosing *induction* period of GSK3745417 in participants with…